Profile data is unavailable for this security.
About the company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
- Revenue in USD (TTM)1.19m
- Net income in USD-444.04m
- Incorporated2017
- Employees557.00
- LocationIovance Biotherapeutics Inc825 INDUSTRIAL ROAD, 4TH FLOORSAN CARLOS 94070United StatesUSA
- Phone+1 (650) 260-7120
- Fax+1 (302) 697-4597
- Websitehttps://www.iovance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.30bn | 251.00 | -- | 3.55 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| SpringWorks Therapeutics Inc | 26.45m | -339.07m | 3.34bn | 305.00 | -- | 5.89 | -- | 126.29 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Fortrea Holdings Inc | 3.11bn | -3.40m | 3.34bn | 18.00k | -- | 1.91 | 35.95 | 1.08 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Janux Therapeutics Inc | 8.08m | -58.29m | 3.35bn | 64.00 | -- | 8.70 | -- | 414.02 | -1.34 | -1.34 | 0.1837 | 7.44 | 0.0217 | -- | -- | 126,296.90 | -15.66 | -- | -16.31 | -- | -- | -- | -721.18 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Axsome Therapeutics Inc | 270.60m | -239.24m | 3.55bn | 545.00 | -- | 18.55 | -- | 13.13 | -5.20 | -5.20 | 5.96 | 4.03 | 0.5885 | 2.68 | 4.08 | 496,513.80 | -52.02 | -64.55 | -69.92 | -82.23 | 90.37 | -- | -88.41 | -227.05 | 3.52 | -35.93 | 0.4825 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 3.55bn | 1.28k | -- | 25.33 | -- | 8.03 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Biohaven Ltd | 0.00 | -408.17m | 3.59bn | 239.00 | -- | 7.71 | -- | -- | -5.67 | -5.67 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -69.48 | -- | -79.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 4.01m | -214.53m | 3.72bn | 290.00 | -- | 5.97 | -- | 926.17 | -3.70 | -3.70 | 0.0691 | 7.91 | 0.0081 | -- | 0.7048 | 13,837.93 | -42.39 | -42.53 | -45.71 | -45.36 | -- | -- | -5,216.32 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.73bn | 271.00 | 26.81 | 2.27 | 23.06 | 2.95 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Insmed Inc | 305.21m | -749.57m | 3.80bn | 912.00 | -- | -- | -- | 12.44 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.81bn | 557.00 | -- | 5.97 | -- | 3,201.81 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Alvotech SA | 93.38m | -551.73m | 3.84bn | 999.00 | -- | -- | -- | 41.15 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Alkermes Plc | 1.73bn | 599.95m | 4.07bn | 2.10k | 6.87 | 3.24 | 6.13 | 2.36 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Immunovant Inc | 0.00 | -243.45m | 4.19bn | 164.00 | -- | 6.16 | -- | -- | -1.83 | -1.83 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -41.70 | -- | -44.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
| Alpine Immune Sciences Inc | 58.88m | -32.18m | 4.24bn | 142.00 | -- | 11.89 | -- | 71.93 | -0.6827 | -0.6827 | 1.18 | 5.43 | 0.1767 | -- | 210.65 | 414,619.70 | -9.66 | -21.93 | -11.36 | -27.81 | -- | -- | -54.66 | -170.16 | -- | -- | 0.00 | -- | 95.84 | 142.30 | 44.28 | -- | -0.3253 | -- |
Data as of May 03 2024. Currency figures normalised to Iovance Biotherapeutics Inc's reporting currency: US Dollar USD
37.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 22.41m | 8.02% |
| Perceptive Advisors LLCas of 20 Feb 2024 | 19.22m | 6.88% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 16.90m | 6.05% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 16.42m | 5.88% |
| Avoro Capital Advisor LLCas of 31 Dec 2023 | 6.70m | 2.40% |
| Pictet Asset Management SAas of 31 Dec 2023 | 5.26m | 1.88% |
| Geode Capital Management LLCas of 31 Dec 2023 | 5.04m | 1.80% |
| Artisan Partners LPas of 31 Dec 2023 | 4.83m | 1.73% |
| Balyasny Asset Management LPas of 31 Dec 2023 | 3.93m | 1.41% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 3.52m | 1.26% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
